Dr. John Jenkins brings more than 25 years of experience at the U.S. Food and Drug Administration (FDA), where he played a leading role in the regulation and development of innovative drugs and biological products. Throughout his FDA career, Dr. Jenkins helped shape regulatory policy, oversee the review and approval of new therapies, and implement major programs affecting drug development and regulation.
From 2002 to 2017, Dr. Jenkins served as Director of the Office of New Drugs (OND) within FDA’s Center for Drug Evaluation and Research (CDER). In this role, he led an organization of more than 1,000 employees across 19 product review divisions and oversaw the review of thousands of new drug applications and biologics license applications, including the approval of more than 400 new molecular entities.
Dr. Jenkins played a significant role in the development and implementation of programs under the Prescription Drug User Fee Act and in applying the statutes and regulations that guide innovative drug development. He also helped lead CDER’s implementation of the biosimilar biologics program under the Biologics Price Competition and Innovation Act and the Biosimilars User Fee Act.
Following his retirement from FDA in 2017 after more than 33 years of federal service, Dr. Jenkins joined Greenleaf Health, now ELIQUENT Life Sciences, where he served as Principal, Drug and Biological Products through 2023. He is currently the owner and managing member of John K. Jenkins Advisors, LLC and serves as an independent director for Corbus Pharmaceuticals and previously for Provention Bio (acquired by Sanofi in 2023).
Dr. Jenkins received numerous awards from FDA and external organizations recognizing his contributions to public health and his work on behalf of patients.